FDA Safety Labeling Change: CORTISPORIN® Ointment — What Changed, What to Update, and How Shudarsana Can Help

What changed (SrLC highlight)

On Aug 8, 2025 (SUPPL-86) the FDA approved an update to Adverse Reactions adding the statement:

“Skin hyperpigmentation has been reported with polymyxin B containing products.” FDA Access Data+1

This is now explicitly listed alongside other topical corticosteroid/antibiotic local reactions and informs clinicians and patients about a pigmentary risk previously not spelled out in the CORTISPORIN label. FDA Access Data

Context from the current label (key guardrails you must keep live)

Indication/limits: For corticosteroid-responsive dermatoses with secondary infection; no additional benefit vs steroid alone after 7 days—therapy should be limited to 7 days. FDA Access Data+1
Contraindications: Not for ocular use; not for external ear canal use if the eardrum is perforated; contraindicated in TB, fungal, or viral skin lesions and in hypersensitivity to components. FDA Access Data
Serious risks already on label: Ototoxicity with neomycin (risk ↑ with prolonged use); cutaneous sensitization to neomycin; risk of overgrowth with prolonged antibiotic use; systemic steroid effects if large areas/occlusion. FDA Access Data

What needs to change internally (Manufacturer/MAH checklist)

Labeling ecosystem & content control

Redline USPI/PI and all downstream assets (HCP slide decks, MI letters, websites/e-IFU/QR landing pages) to include the skin hyperpigmentation statement in Adverse Reactions; keep 7-day limit and non-ocular use warnings prominent in cross-references. FDA Access Data+1

Medical information & customer communications

Update standard responses and field FAQs to address pigmentary changes with polymyxin B products: description, expected course, when to stop therapy, and when to refer. FDA Access Data

Packaging & pharmacy materials

Re-issue patient handouts/leaflets to include hyperpigmentation among local AEs; ensure “do not use in the eyes,” “limit to 7 days,” and perforated eardrum caution remain conspicuous. FDA Access Data+1

Training

Brief sales/medical teams and call center staff on differentiating hyperpigmentation vs. hypopigmentation (also listed for topical steroids) and on counseling for cessation/medical evaluation if pigmentary changes arise. FDA Access Data

Pharmacovigilance (PV) impact

Case intake & coding

Add skin hyperpigmentation (and existing hypopigmentation) to adverse event intake prompts and MedDRA coding checks; capture onset relative to treatment start, application site, duration (note: label caps therapy at ≤7 days), and resolution after discontinuation. FDA Access Data+1

Triage & seriousness assessment

Most pigmentary events will be non-serious, but create rules to escalate if associated with widespread dermatitis, severe inflammation, or suspected steroid/antibiotic misuse (e.g., prolonged/occlusive use). FDA Access Data

Aggregate safety (PBRER/PSUR)

Add a targeted signal topic for polymyxin-associated hyperpigmentation: exposure-adjusted reporting rates, demographics, application sites (face/intertriginous areas), and outcomes. Analyze co-reported terms (burning, irritation, dermatitis) and steroid-related effects. FDA Access Data

Risk communication

Update HCP safety letters/FAQs to include pigmentary risk and reinforce 7-day limit, non-ocular use, and avoid use in perforated eardrum. FDA Access Data+1

Regulatory impact

United States

File labeling supplements as applicable in your lifecycle system and synchronize e-label repositories so that payer/compendia and third-party references pull the updated AR text. Maintain change-control tracing the SrLC item to the specific label lines. FDA Access Data

Global alignment

Update CCDS/Core PI with the pigmentary risk statement; for local markets using class labeling for polymyxin B-containing products, harmonize wording and justify translation choices in annotated labels. Where patient leaflets are mandated, ensure the pigment change is described in patient-friendly language. (Inference aligned to U.S. update.) FDA Access Data

Promotion & A&P

Re-review all promotional copy for fair balance—add the new pigmentary risk to risk summaries; keep ototoxicity and duration limits in balance boxes for any materials that may trigger extended use. FDA Access Data

What Shudarsana can do (fast, actionable support)

24-Hour Labeling Redline Pack

Incorporate the hyperpigmentation addition in AR; refresh cross-refs to 7-day limit/contraindications; deliver updated USPI/PI, annotated PDFs, and a change-control memo tying SrLC → sections/lines. FDA Access Data+2FDA Access Data+2

PV Upgrade Sprint (7–10 days)

Update case intake scripts, MedDRA term lists, and signal review templates; add pigmentary AE dashboards; train safety staff with mock cases (disposition rules, follow-up asks, photo documentation SOP). FDA Access Data

Regulatory & MI Enablement

Prepare Dear HCP and MI standard responses; align patient leaflets and pharmacy shelf-talkers emphasizing correct use (thin film, 2–4×/day, ≤7 days; stop if irritation or pigment change); verify website/e-IFU updates. FDA Access Data+1

Quality & Compliance Audit

Rapid audit of A&P materials for fair balance; ensure contraindications (e.g., perforated eardrum, ocular use) and key warnings are consistently surfaced. FDA Access Data

Bottom line

The FDA’s addition of skin hyperpigmentation to CORTISPORIN’s Adverse Reactions section is a focused but important refinement. It should immediately cascade into label text, PV capture/analytics, HCP & patient communications, and promotional balance—with a special emphasis on short treatment duration and site-appropriate use to minimize risk. FDA Access Data+1

Discover more from सुदर्शन

Subscribe to get the latest posts sent to your email.